Merck & Co., Inc. (NYSE:MRK) Posts Earnings Results, Beats Estimates By $0.13 EPS

Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13, FiscalAI reports. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the company earned $2.13 EPS. Merck & Co., Inc. updated its FY 2026 guidance to 2.660-2.760 EPS.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Merck raised and narrowed its 2026 revenue outlook to $66.3 billion–$67.3 billion, while maintaining confidence in continued growth driven by oncology, animal health, and newer product launches.
• New and expanding products showed strong momentum, including WINREVAIR sales up 75%, WELIREG sales up 67%, and CAPVAXIVE sales up 40%; LIPFENDRA also received FDA approval as the first oral PCSK9 inhibitor.
• Pipeline de-risking accelerated, with positive Phase III results for sac-TMT in endometrial cancer and tulisokibart in ulcerative colitis, while weekly oral HIV-treatment data and multiple upcoming regulatory milestones support Merck’s projected long-term growth opportunities.
• Second-quarter reported EPS was a loss of $0.13, including a $2.31-per-share one-time charge tied to the Terns acquisition; Merck also expects U.S. KEYTRUDA growth to moderate, an OHTUVAYRE sales unwind in the third quarter, and higher inventory reserves to pressure margins.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK traded up $1.29 on Tuesday, reaching $129.06. The company’s stock had a trading volume of 3,837,913 shares, compared to its average volume of 10,764,296. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $135.05. The stock has a market capitalization of $318.76 billion, a P/E ratio of 36.42, a PEG ratio of 5.17 and a beta of 0.19. The stock’s 50-day moving average is $123.28 and its two-hundred day moving average is $118.66. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Hedge Funds Weigh In On Merck & Co., Inc.

Several institutional investors have recently added to or reduced their stakes in MRK. State Street Corp grew its stake in shares of Merck & Co., Inc. by 1.6% in the 4th quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after purchasing an additional 1,859,990 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the last quarter. Morgan Stanley raised its stake in shares of Merck & Co., Inc. by 0.8% during the fourth quarter. Morgan Stanley now owns 44,946,021 shares of the company’s stock worth $4,731,018,000 after purchasing an additional 359,486 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Merck & Co., Inc. by 6.1% during the fourth quarter. Bank of America Corp DE now owns 27,854,441 shares of the company’s stock worth $2,931,958,000 after purchasing an additional 1,602,005 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after buying an additional 5,152,069 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate and up 5.1% year over year. The company also posted a narrower-than-expected loss of $0.13 per share, compared with the expected $0.26 loss. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth driver, while the newer injectable formulation reportedly generated more than $200 million above Wall Street’s forecast. Strength in oncology and other newer products helped Merck raise its full-year revenue guidance to $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion consensus. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Neutral Sentiment: Management highlighted regulatory approvals, clinical progress and a broad development pipeline, which could support longer-term growth as Merck works to diversify beyond Keytruda. Merck announces second-quarter 2026 financial results and pipeline milestones
• Negative Sentiment: Merck cut its fiscal 2026 adjusted EPS guidance to $2.66-$2.76, well below the $3.42 analyst consensus. The reduction reflects acquisition-related charges, particularly costs tied to the purchase of Terns Pharmaceuticals, and overshadows the quarterly earnings beat. Merck hikes revenue outlook but cuts profit guidance due to deal charges
• Negative Sentiment: The quarterly loss compares with earnings of $2.13 per share in the year-ago period, underscoring the near-term impact of acquisition and investment costs on profitability. Merck reports second-quarter loss and beats revenue estimates

Analyst Upgrades and Downgrades

A number of analysts have weighed in on MRK shares. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Guggenheim lifted their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. UBS Group upped their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Cantor Fitzgerald reiterated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Finally, Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Thirteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $134.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.